Aspera Biomedicines Successfully Launches Second ADAR1p150 Protein Crystallization Experiment to the International Space Station Aboard SpaceX CRS-34
Aspera Biomedicines Inc., a biotechnology company focused on developing first-in-class therapies targeting cancer stem cells, has successfully launched its second ADAR1p150 protein crystallization experiment to the International Space Station (ISS). The mission was carried aboard the SpaceX CRS-34 commercial resupply flight, marking another milestone in the company’s expanding space-based biomedical research program.
This latest mission represents Aspera’s 11th overall International Space Station experiment, reinforcing its position as one of the leading biotechnology companies leveraging microgravity environments for drug discovery and structural biology. The newly launched crystallization study builds on prior success and is now actively operating in microgravity aboard the ISS.
Successful Launch Following Weather Delays
The CRS-34 mission faced two weather-related launch scrubs earlier in the week before successfully lifting off. The SpaceX Falcon 9 rocket launched at 6:05 PM EDT on Friday, May 15, from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.
After liftoff, the Dragon spacecraft began its journey carrying Aspera’s sensitive crystallization payload to low Earth orbit. Following an approximately 36-hour transit period, the spacecraft autonomously docked with the forward port of the ISS Harmony module at 6:37 AM EDT on Sunday, May 17. This docking occurred slightly ahead of the originally scheduled 7:00 AM EDT target time, reflecting the precision and efficiency of the mission’s orbital operations.
With successful docking completed, Aspera’s ADAR1p150 crystallization experiment was transferred into the ISS research environment, where it is now functioning under microgravity conditions. The experiment is expected to generate high-quality protein crystal structures that are difficult or impossible to achieve on Earth due to gravitational and convection-related limitations.
Expanding Aspera’s Space-Based Biotechnology Platform
This mission follows Aspera Biomedicines’ inaugural ADAR1p150 crystallization experiment, which was launched aboard SpaceX Crew-12 in February 2026. Together, these missions represent a growing pipeline of space-enabled biomedical research initiatives designed to accelerate drug discovery and improve structural understanding of critical cancer-related proteins.
The program is funded through NASA’s In Space Production Applications (InSPA) Phase 2 award, a competitive initiative that supports commercial development of technologies that take advantage of microgravity environments. As part of this program, Aspera is utilizing Redwire Corporation’s Pharmaceutical In-space Laboratory (PIL-BOX) platform, which is specifically designed to support protein crystallization and other advanced biological experiments in orbit.
Microgravity provides a unique scientific environment where the absence of sedimentation and reduced convection allows proteins to crystallize more uniformly and with fewer defects. This enables researchers to obtain more precise and detailed molecular structures, which are essential for rational drug design.
By using the ISS as a research platform, Aspera aims to overcome significant limitations in traditional ground-based crystallography, where gravity-induced imperfections often reduce the quality of protein crystals and limit structural resolution.
Scientific Significance of ADAR1p150 Research
At the center of this mission is ADAR1p150, a stress-response protein that plays a critical role in cancer biology. ADAR1 is known for its ability to edit RNA molecules, a process that cancer cells exploit to evade immune detection and survive under therapeutic pressure.
Cancer stem cells, in particular, often overexpress ADAR1, allowing them to resist treatment and contribute to tumor recurrence. These cells are considered one of the primary drivers of relapse in many aggressive cancers.
Aspera’s investigational drug, Rebecsinib, is designed as a selective inhibitor of ADAR1. It acts as a “kill switch” for cancer stem cells by disrupting their ability to survive and regenerate while sparing normal healthy cells. This targeted mechanism of action positions Rebecsinib as a potentially transformative therapy across multiple cancer types.
The current crystallization experiments aim to reveal the precise atomic structure of ADAR1p150, both in its unbound form and when complexed with Rebecsinib. These high-resolution structural insights are expected to play a crucial role in understanding how the drug interacts with its target at a molecular level.
Such data are essential for medicinal chemistry optimization, enabling researchers to refine drug candidates and improve properties such as binding affinity, stability, and bioavailability. Ultimately, these insights could accelerate the development of an oral formulation of Rebecsinib, expanding patient accessibility and simplifying treatment administration.
Expert Perspective on the Mission
Dr. Catriona Jamieson, Founder and Board Member of Aspera Biomedicines and a leading researcher in cancer stem cell biology, emphasized the importance of the mission in advancing both scientific understanding and clinical development.
According to Dr. Jamieson, this second crystallization mission represents a significant step forward in elucidating the mechanism of action of ADAR1 inhibition and advancing Rebecsinib toward broader clinical use.
She highlighted that the work being conducted aboard the ISS is not only focused on structural biology but also on translating those findings into therapeutic innovation. By leveraging microgravity-enabled crystallization, the company aims to accelerate the development of an oral formulation of Rebecsinib that could potentially address a wide range of advanced malignancies.
Dr. Jamieson noted that ADAR1 is implicated in more than 20 different cancer types, including acute myeloid leukemia, glioblastoma, ovarian cancer, and other high-risk malignancies. This broad expression profile underscores the potential impact of ADAR1-targeted therapies in oncology.
Mechanism of Action: Targeting Cancer Stem Cells
Cancer stem cells are a subpopulation of tumor cells that possess the ability to self-renew and drive tumor growth. They are often resistant to conventional therapies such as chemotherapy and radiation, which can eliminate the bulk of tumor cells but leave behind these resilient cells.
ADAR1 plays a key role in helping these cancer stem cells survive by editing RNA and modulating immune signaling pathways. This enables tumor cells to evade immune surveillance and continue proliferating even after treatment.
Rebecsinib disrupts this process by inhibiting ADAR1 activity, effectively removing a critical survival mechanism used by cancer stem cells. As a result, the therapy aims to prevent tumor relapse and “malignant regeneration,” a process in which cancer re-emerges after initial treatment success.
The ability to target this fundamental biological pathway positions Rebecsinib as a potentially first-in-class therapy with broad applicability across multiple cancer indications.
Clinical Development and Regulatory Progress
Rebecsinib has already received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration under IND #153126. This regulatory milestone allows the compound to be evaluated in human clinical trials.
The company is preparing to initiate a Phase 1 clinical trial targeting patients with high-risk myelofibrosis and secondary acute myeloid leukemia. Patient recruitment is expected to begin within the coming weeks, marking an important transition from preclinical development to early-stage human testing.
Given that ADAR1 is overexpressed in a wide range of cancers, Aspera is also evaluating the broader therapeutic potential of Rebecsinib across multiple oncology indications. Future development efforts include not only expanded clinical trials but also the advancement of next-generation ADAR1 inhibitors and oral drug formulations designed to improve patient compliance and accessibility.
The Role of Space in Modern Drug Discovery
Aspera Biomedicines is part of a growing movement of biotechnology companies leveraging space-based platforms for advanced research. The unique conditions aboard the ISS allow scientists to conduct experiments that are not feasible on Earth, particularly in fields such as protein crystallization, tissue engineering, and materials science.
Microgravity eliminates many of the physical forces that interfere with molecular assembly, enabling more ordered and higher-quality crystal growth. These improvements are particularly valuable in drug discovery, where detailed structural information is essential for designing highly specific therapeutic agents.
By integrating space-based research into its drug development pipeline, Aspera aims to shorten development timelines and improve the precision of its therapeutic design process.
Company Overview and Future Outlook
Aspera Biomedicines is a space-accelerated biotechnology company dedicated to developing therapies that target cancer stem cells, the root cause of cancer recurrence. Founded by Dr. Catriona Jamieson, the company holds an exclusive license to Rebecsinib, a first-in-class ADAR1 inhibitor.
To date, Aspera has secured more than $40 million in non-dilutive funding, supporting its innovative research programs and space-based experiments. The company is currently pursuing a $35 million Series A funding round to accelerate clinical development, expand its research capabilities, and advance additional pipeline programs targeting cancer stem cell biology.
Aspera’s long-term vision is to transform cancer treatment by combining cutting-edge molecular biology with space-enabled drug discovery platforms. By doing so, the company hopes to develop therapies that not only treat cancer more effectively but also prevent recurrence by eliminating its root cellular drivers.
About Aspera Biomedicines
Aspera Biomedicines is a space-accelerated biotechnology company pioneering therapies that target cancer stem cells — the root cause of cancer relapse. Founded by Dr. Catriona Jamieson, a leading cancer stem cell researcher, Aspera holds an exclusive license to Rebecsinib, a first-in-class ADAR1 inhibitor. The company has secured over $40 million in non-dilutive funding and is currently raising a $35 million Series A to accelerate clinical development.
